4-methyl-1-hepten-3-one | 518346-31-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methyl-1-hepten-3-one
• 英文别名: 4-methylhept-1-en-3-one
• CAS: 518346-31-1
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: FMZDFRXBZBPNSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-methyl-1-hepten-3-one 、 methyl 4-(2-(5-oxopyrazolidin-1-yl)ethyl)benzoate 以 乙醇 为溶剂， 反应 2.0h， 生成 Methyl 4-[2-[2-(4-methyl-3-oxoheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate
  参考文献：
  名称：

  Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists

  摘要：

  Replacement of the hydroxy cyclopentanone ring in PGE(2) with chemically more stable heterocyclic rings and substitution of the unsaturated alpha-alkenyl chain with a metabolically more stable phenethyl chain led to the development of potent and selective analogs of PGE(2). Compound 10f showed the highest potency and selectivity for EP4 the receptor. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.074
• 作为产物：
  描述：

  N-methoxy-N,2-dimethylpentanamide 、 乙烯基溴化镁 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-methyl-1-hepten-3-one
  参考文献：
  名称：

  Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists

  摘要：

  Replacement of the hydroxy cyclopentanone ring in PGE(2) with chemically more stable heterocyclic rings and substitution of the unsaturated alpha-alkenyl chain with a metabolically more stable phenethyl chain led to the development of potent and selective analogs of PGE(2). Compound 10f showed the highest potency and selectivity for EP4 the receptor. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.074

文献信息

• Process for producing 2,2'-bis-(hydroxymethyl)alkanal and 2,2'-bis(hydroxymethyl)alkanoic acid
  申请人：Nippon Kasei Chemical Company Limited

  公开号：EP1179523A1

  公开（公告）日：2002-02-13

  The present invention relates to a process for producing 2,2'-bis(hydroxymethyl)alkanal and 2,2'-bis(hydroxymethyl)alkanoic acid as raw materials for dimethylol alkanoic acids or trimethylol alkanes, which are useful for the production of polyesters, polyurethanes, alkyd resins and the like, in an industrially advantageous manner.

  本发明涉及一种生产2,2'-双(羟甲基)烷基醛和2,2'-双(羟甲基)烷基酸的工艺，作为二甲醛烷基酸或三甲醇烷基的原材料，这些原材料对于聚酯、聚氨酯、醇酸树脂等的生产具有工业优势。
• [EN] PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS<br/>[FR] COMPOSES DE PYRAZOLIDINONE UTILISES COMME LIGANDS DES RECEPTEURS EP2 ET/OU EP4 AUX PROSTAGLANDINES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003035064A1

  公开（公告）日：2003-05-01

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑烷酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物可用于多种治疗，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血液凝块、先兆子痫或子痫、嗜酸性粒细胞障碍、性功能障碍、骨质疏松症和其他破坏性骨疾病或障碍，以及与前列腺素EP2和/或EP4受体相关的其他疾病和障碍。
• Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
  申请人：——

  公开号：US20040254233A1

  公开（公告）日：2004-12-16

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑啉酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物对于各种疗法都有用，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血栓形成、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他破坏性骨疾病或疾病，以及与前列腺素EP2和/或EP4受体相关的其他疾病和疾病。
• PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS
  申请人：ARALDI Gian Luca

  公开号：US20080234346A1

  公开（公告）日：2008-09-25

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑烷酮化合物，以及利用或包含一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物可用于多种治疗，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血凝、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他与前列腺素EP2和/或EP4受体相关的疾病和障碍。
• Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
  申请人：Laboratoires Serono S.A.

  公开号：US07410991B2

  公开（公告）日：2008-08-12

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  该发明提供了取代的吡唑啉酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。该发明的化合物对于各种治疗非常有用，包括治疗或预防早产、痛经、哮喘、高血压、不育或生育障碍、不良的血液凝块、妊娠高血压综合症或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他破坏性骨疾病或障碍，以及与前列腺素EP2和/或EP4受体相关的其他疾病和障碍。